Trial Profile

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN-COVID-19)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 11 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AB 201 (Primary) ; Heparin
Indications Blood coagulation disorders; COVID 2019 infections
Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
Acronyms ASPEN; ASPEN-COVID-19
Sponsors ARCA biopharma Inc

Most Recent Events

01 Aug 2023 Results published in the Arteriosclerosis Thrombosis and Vascular Biology
07 Nov 2022 Interim results assessing efficacy and safety of Title Novel Tissue Factor Inhibition For Thromboprophylaxis In COVID-19 presented at the American Heart Association Scientific Sessions 2022
31 Mar 2022 Primary endpoint (Change in D-dimer level from Baseline to Day 8 (Phase 2b)) has not been met as per results published in the ARCA biopharma Inc Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com